$15.33
3.41% today
Nasdaq, Sep 15, 07:43 pm CET
ISIN
US5907171046
Symbol
MESO

Mesoblast Limited Sponsored ADR Stock price

$14.82
-0.03 0.20% 1M
+1.37 10.19% 6M
-4.98 25.15% YTD
+8.45 132.65% 1Y
+8.32 128.00% 3Y
-19.78 57.17% 5Y
-8.76 37.15% 10Y
+5.32 56.00% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-0.55 3.58%
ISIN
US5907171046
Symbol
MESO
Industry

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$1.9b
Net debt
positive
Cash
$161.2m
Shares outstanding
1.3b
Valuation (TTM | estimate)
P/E
negative | negative
P/S
114.8 | 29.5
EV/Sales
112.9 | 29.1
EV/FCF
negative
P/B
3.3
Financial Health
Equity Ratio
76.1%
Return on Equity
-17.1%
ROCE
-12.1%
ROIC
-14.1%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$17.2m | $66.8m
EBITDA
- | $-42.1m
EBIT
$-82.3m | $-50.7m
Net Income
$-102.1m | $-237.6m
Free Cash Flow
$-50.6m
Growth (TTM | estimate)
Revenue
191.5% | 288.5%
EBITDA
- | 48.9%
EBIT
-23.0% | 38.4%
Net Income
-16.1% | -132.6%
Free Cash Flow
-3.9%
Margin (TTM | estimate)
Gross
70.2%
EBITDA
- | -63.0%
EBIT
-478.5%
Net
-593.9% | -355.6%
Free Cash Flow
-294.4%
More
EPS
$-0.1
FCF per Share
$0.0
Short interest
2.6%
Employees
73
Rev per Employee
$240.0k
Show more

Is Mesoblast Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Mesoblast Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

Buy
80%
Hold
20%

Financial data from Mesoblast Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
17 17
192% 192%
100%
- Direct Costs 5.13 5.13
67% 67%
30%
12 12
223% 223%
70%
- Selling and Administrative Expenses 39 39
66% 66%
229%
- Research and Development Expense 35 35
37% 37%
202%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -82 -82
23% 23%
-478%
Net Profit -102 -102
16% 16%
-594%

In millions USD.

Don't miss a Thing! We will send you all news about Mesoblast Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mesoblast Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
about 17 hours ago
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® (remestemcel-L-rknd), the only mesenchymal stromal cell (MSC) product approved by the United States Food and Drug Administration (FDA), was highlighted this past week in presen...
Neutral
GlobeNewsWire
12 days ago
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck (“Investors”) to issue, at its sole discretion, up to US$50.0 ...
Neutral
Seeking Alpha
17 days ago
Mesoblast Limited (NASDAQ:MESO ) Q4 2025 Earnings Conference Call August 28, 2025 6:30 PM ET Company Participants Andrew Chaponnel - Interim Chief Finance Officer Marcelo Santoro - Chief Commercial Officer Silviu Itescu - Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Conference Call Participants Edward Andrew Tenthoff - Piper Sandler & Co., Research Division Elyse...
More Mesoblast Limited Sponsored ADR News

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Silviu Itescu
Employees 73
Founded 2004
Website www.mesoblast.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today